Navigation Links
FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
Date:4/25/2008

f Executive Officer of Isis. "Conducting an outcome study in parallel with our continued evaluation of the effects of mipomersen on atherogenic lipids will allow us to submit a much stronger NDA for high risk patients. We are confident that mipomersen will bring benefit to patients with high cholesterol and remain committed to its development and commercialization."

"We are pleased that the FDA has given clear direction on what will be required for the approval of mipomersen, and has acknowledged its potential to help high risk patients whose needs are not being met by current therapies," said Henri A. Termeer, Genzyme's chairman and chief executive officer. "Having outcome data earlier on in the development process will be important to patients and serve to enhance the value of this treatment. We plan to engage in discussions with regulatory agencies in Europe and the rest of the world, and look forward to receiving their feedback."

ABOUT MIPOMERSEN

In early 2008, Isis and Genzyme announced that they had entered into a strategic alliance in which Genzyme will develop and commercialize mipomersen. Final contracts are still being negotiated and are expected to be completed this quarter.

Mipomersen is a second-generation antisense drug that reduces the production of apoB-100, a protein critical to the synthesis and transport of "bad" cholesterol. Cholesterol can be carried in the bloodstream in a variety of forms, with high-density lipoprotein, or HDL-cholesterol, being the good form, and low-density lipoproteins, or LDL-cholesterol, and very low-density lipoproteins, or VLDL-cholesterol, being bad forms directly involved in heart disease. Collectively lowering LDL-cholesterol, VLDL-cholesterol, and other bad forms of cholesterol are a key component in the prevention and management of cardiovascular disease.

Mipomersen is currently in phase 3 development for patients with homozygous familial hypercholesterolemia, a disease which crea
'/>"/>

SOURCE Genzyme Corp. and Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Study provides hope that some transplant patients could live free of antirejection drugs
2. Study provides hope that some transplant patients could live free of anti-rejection drugs
3. USAID Provides Additional Wildfire Assistance to Greece
4. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
5. New knock-out gene model provides molecular clues to breast cancer
6. PreMD Provides Update on 510(k) Application for PREVU(x) POC
7. SIV infection of natural hosts provides new insights into HIV disease complexity
8. Microarray provides 3 genomic guides to breast cancer treatment decisions
9. Access Innovations Provides Support Services for Agis Network
10. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
11. Physical Therapist Provides Injury Analysis for Fantasy Football
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2015)... Aliso Viejo, CA (PRWEB) April 26, 2015 ... Final Cut Pro X editors can quickly and ... a Lookup Table that contains a mathematical formula for modifying ... corresponding color indicated by the table. This pack comes with ... was inspired by vintage and contemporary black and white films. ...
(Date:4/26/2015)... (PRWEB) April 26, 2015 This annual ... of the season and will include a spectacular collection ... totes, collectibles, herbal soaps and incense, chimes, vases, candleholders, ... this year’s exciting and unique collection of vendors, guests ... with Jim Martocci and the Jimmie Jazz Band. ...
(Date:4/26/2015)... Memphis, TN (PRWEB) April 26, 2015 ... plans to grow throughout the Southeast. MidSouth Pain Treatment ... clinic locations in Cordova, Southaven, Oxford and Jackson, two ... CLIA-certified laboratory in the Southaven and Cordova locations. , ... said ”I went into medicine to help people, ...
(Date:4/25/2015)... April 25, 2015 In observance of ... join The Million Nets Pledge, a two-year pledge by ... protect refugee families with one million bednets by 2016. ... work with UN partners to protect children, refugees, and ... , “There has been a large surge in ...
(Date:4/25/2015)... Carinsurancequotesinfo.com has released a new blog post ... insurance for flatbed trucks. , Flatbed trucks ... vehicles. They are mainly used for commercial purposes and ... post explains that by comparing multiple offers, drivers can ... commercial vehicles. , It is now possible to compare ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios, a FCPX Effects Developer, Announced the Release of FCPX LUT B&W 2Health News:It’s Coming! The 5th Annual Tulip Festival & Mother’s Day Celebration at Honor's Haven Resort & Spa! 2Health News:Growing Pains for MidSouth Pain Treatment Center 2Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 2Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 3Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 4Health News:Auto Insurance Quotes for Flatbed Trucks Available Online! 2
... majority of advanced colon cancer patients in a clinical ... drugs for managing chemotherapy side effects, such as infection, ... drug cost burdens after joining the clinical trial, according ... Institute in Boston. Although few patients reported substantial worry ...
... -- PRA International, a leading Clinical Research ... audioconference and announces it will exhibit at the 2009 ... Florida, May 30 through June 1. The audioconference, which ... 2009, and was presented by John Constant, PhD, PRA,s ...
... U.S. Food and Drug Administration (FDA) announced today that ... for Pharmaceutical Science and Clinical Pharmacology to discuss bioequivalence ... The meeting is scheduled for August 4, 2009. ... no later than two days before the meeting at ...
... 29 The J. Craig Venter Institute (JCVI) announced ... five year contract from the National Institute of Allergy ... of Health, as one of their Genomic Sequencing Centers ... Nierman, Ph.D., and Robert Strausberg, Ph.D., the contract will ...
... DeterminedToQuit.com translated to Estoydecidido.com for Latino PennsylvaniansHARRISBURG, ... Health Everette James today announced the launch ... Latino residents of Pennsylvania go tobacco free.Estoydecidido.com ... - is the Spanish version of the ...
... finds student military veterans face some unique health issuesMINNEAPOLIS/ST. ... expected to go to school this fall as a ... will need to ensure student veterans, unique needs are ... issued Friday by the University of Minnesota ...
Cached Medicine News:Health News:One in ten advanced colon cancer patients worry about prescription drug costs 2Health News:PRA International Oncology Experts at ASCO 2Health News:ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products 2Health News:ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products 3Health News:ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products 4Health News:J. Craig Venter Institute Awarded $43 Million, Five Year Contract From NIAID to Continue to Develop and Provide Sequencing, Genotyping, and Bioinformatics Expertise and Services in Infectious Diseases 2Health News:J. Craig Venter Institute Awarded $43 Million, Five Year Contract From NIAID to Continue to Develop and Provide Sequencing, Genotyping, and Bioinformatics Expertise and Services in Infectious Diseases 3Health News:PA Department of Health Launches Spanish-Language Smoking Cessation Resource Web Site 2Health News:Student Veteran Health Examined in First-of-Its-Kind Study by University of Minnesota/Minnesota State Colleges and Universities 2Health News:Student Veteran Health Examined in First-of-Its-Kind Study by University of Minnesota/Minnesota State Colleges and Universities 3
(Date:4/23/2015)...  AbbVie (NYSE: ABBV ) has announced that ... its New Drug Application (NDA) and granted priority review ... of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV). The ... genotype 4 (GT4) hepatitis C virus (HCV) infection. ... being evaluated by the FDA for patients in ...
(Date:4/23/2015)... , April 23, 2015 Once again, ... strengthening our commitment to patient safety. BeaconMedaes, ... fight against infectious disease. The next generation ... Medical gas sensors are now mounted in the assembly, ... need to open ceiling tiles potentially releasing dust spores ...
(Date:4/23/2015)... FRANCISCO , April 23, 2015 Nektar Therapeutics ... the first quarter ended March 31, 2015 on Thursday, April ... Howard Robin , president and chief executive officer, will host ... p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... the conference call can be accessed through a link that ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets 2
... Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company ... from its consumer trial with Allumera™, a breakthrough cosmetic ... The RevitAll study was performed with a standard ... Allumera™ improves skin appearance, when compared to exposure by ...
... Inc. (Hologic or the Company) (Nasdaq: ... of premium diagnostics products, medical imaging systems and ... of women, announced today the U.S. Food and ... Makena™ (hydroxyprogesterone caproate injection), formerly known as Gestiva™. ...
Cached Medicine Technology:Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 2Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 3Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 4FDA Approves Hologic's Makena™ (Formerly Referred to as Gestiva™) Pharmaceutical 2
... is now the first manufacturer to ... to the wearer. These next generation ... clarity, an ultra-lightweight design, and are ... scratch resistance. With SheerVision's proprietary SureFit ...
For face-lifts and submental liposuction...
Ideal for autoplasty and liposuction of chin and cheeks...
Facial Mask...
Medicine Products: